Type Diabetes Clinical Trials 2024
Here are the 6 most popular medical studies for type 1 diabetes
Cell Therapy
Islet Cell Transplant for Type 1 Diabetes
This trial is testing if it's safe to transplant human islet cells to help control blood sugar in type 1 diabetes patients who have trouble controlling it. Early observations will also be made about if this treatment can help with hypoglycemia.
Teplizumab for Type 1 Diabetes
This trial is for people who have developed type 1 diabetes after taking part in another trial testing a different diabetes treatment. The people in this trial will receive teplizumab, which may help to prevent or delay the onset of type 1 diabetes.
Synthetic Amylin Analog
Pramlintide + Insulin with Artificial Pancreas for Type 1 Diabetes
This trial is testing whether adding pramlintide, a synthetic analog of the hormone amylin, to a closed-loop system will better normalize glucose levels in adults with Type 1 Diabetes, especially during the post-prandial period.
Supportive Intervention for Type 1 Diabetes
This trial will test a new intervention to help 16-21 year olds with Type 1 Diabetes better manage their disease. The intervention is based on the idea that if these young adults feel more in control and supported, they will be more likely to stick to their care routine. If successful, this intervention could be used to help other groups manage chronic illnesses.
Behavioral Intervention
Mindfulness-Based Stress Reduction for Diabetes
This trial will compare the effects of an online mindfulness-based stress reduction intervention to an active control stress management education on glucose control in adults with uncontrolled type 1 or type 2 diabetes.
Popular filter options for type 1 diabetes trials
T1D Clinical Trials
View 92 T1D medical studies.
GLP-1 Receptor Agonist
Stem Cell Mobilization + Immunotherapy for Type 1 Diabetes
This trial is based on the "immunological reset" approach to treat type 1 diabetes. T-depletion therapy and anti-inflammatory treatment will restore self-tolerance in T1DM patients. Autologous, peripheral-blood mobilized hematopoietic CD34+-enriched stem cells and a long-acting GLP-1 analogue will promote pancreatic islet regeneration and repair.
Islet Cell Transplantation
Islet Cell Transplant for Type 1 Diabetes
This trial is testing whether islet transplantation is safe for people with Type 1 diabetes. Islets are clusters of cells that produce insulin, and the trial will use islets from cadaver donors.
Diabetes Clinical Trials
View 16 Diabetes medical studies.
Maternal Enteroviral Infection and Diabetes Impact on Congenital Heart Defects
This trial is looking at the role of maternal viral infections in Congenital Heart Disease (CHD). They will be looking at samples from two existing biorepositories and also doing a prospective study.
Behavioral Intervention
Parent Group Education for Adolescent Type 1 Diabetes Transition
This trial will study if group education for parents of adolescents with type 1 diabetes will improve the transition from adolescence to adulthood. They will do this by conducting a pilot randomized controlled trial of parent group education sessions to assess the feasibility and refine the intervention.
ZnT8 Positive Clinical Trials
View 8 ZnT8 positive medical studies.
GLP-1 Receptor Agonist
Stem Cell Mobilization + Immunotherapy for Type 1 Diabetes
This trial is based on the "immunological reset" approach to treat type 1 diabetes. T-depletion therapy and anti-inflammatory treatment will restore self-tolerance in T1DM patients. Autologous, peripheral-blood mobilized hematopoietic CD34+-enriched stem cells and a long-acting GLP-1 analogue will promote pancreatic islet regeneration and repair.
Mesenchymal Stem Cells
Stem Cell Therapy for Type 1 Diabetes
This trial will test whether fresh, donor-derived mesenchymal stem cells can safely and effectively treat new-onset type 1 diabetes. If successful, this could provide a new therapeutic option for patients with this and other autoimmune disorders.
IA-2 Positive Clinical Trials
View 6 IA-2 positive medical studies.
Mesenchymal Stem Cells
Stem Cell Therapy for Type 1 Diabetes
This trial will test whether fresh, donor-derived mesenchymal stem cells can safely and effectively treat new-onset type 1 diabetes. If successful, this could provide a new therapeutic option for patients with this and other autoimmune disorders.
Dendritic Cell Therapy
Dendritic Cell Therapy for Type 1 Diabetes
This trial will test if a new treatment for Type I Diabetes Mellitus (T1DM) is safe and effective. The treatment involves using the patient's own cells to create immunoregulatory dendritic cells (iDC). These iDC will be treated with antisense DNA and then injected back into the patient. The goal is to see if this treatment will safely preserve and/or increase B-cell mass, resulting in better blood sugar control.
Phase 3 Type 1 Diabetes Clinical Trials
View 97 phase 3 type 1 diabetes medical studies.
Insulin
Inhaled Insulin for Diabetes in Children
This trial is testing the efficacy and safety of Afrezza, a inhaled insulin, in children with type 1 or 2 diabetes. The trial has a screening and run-in period of up to 5 weeks, followed by a 26-week randomized treatment period, during which subjects will receive either Afrezza or a rapid-acting insulin injection. All subjects will then enter a 26-week treatment extension, during which they will receive Afrezza. The trial will conclude with a 4-week follow-up period.
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
Semaglutide + Closed-Loop Therapy for Type 1 Diabetes
This trial is testing if semaglutide, a once-weekly injectable medication, can improve glucose control in those with type 1 diabetes when used with a closed-loop insulin system.
Autoantigen-based Therapy
DIAGNODE-3 study for recently diagnosed type I diabetes
The DIAGNODE-3 study is testing an investigational drug called Diamyd (rhGAD65) to see if it is able to preserve the body's own insulin-producing capacity by halting or delaying the autoimmune attack on the beta cells. Sustained beta cell function is associated with better metabolic control and a lower risk of low blood sugars and chronic complications..
Glucagon-like peptide-1 receptor agonist
Semaglutide for Type 1 Diabetes
This trial will assess the effects of semaglutide, a medication not approved by the FDA, on people with type 1 diabetes. It may reduce CV disease and kidney disease and improve glucose control and BMI.
Type 1 Diabetes Clinical Trials With No Placebo
View 97 type 1 diabetes medical studies that do not have a placebo group.
GLP-1 Receptor Agonist
Stem Cell Mobilization + Immunotherapy for Type 1 Diabetes
This trial is based on the "immunological reset" approach to treat type 1 diabetes. T-depletion therapy and anti-inflammatory treatment will restore self-tolerance in T1DM patients. Autologous, peripheral-blood mobilized hematopoietic CD34+-enriched stem cells and a long-acting GLP-1 analogue will promote pancreatic islet regeneration and repair.
Islet Cell Transplantation
Islet Cell Transplant for Type 1 Diabetes
This trial is testing whether islet transplantation is safe for people with Type 1 diabetes. Islets are clusters of cells that produce insulin, and the trial will use islets from cadaver donors.
View More Type 1 Diabetes Trials
See another 69 medical studies focused on type 1 diabetes.
Frequently Asked Questions
Introduction to type 1 diabetes
What are the top hospitals conducting type 1 diabetes research?
When it comes to advancing the treatment and understanding of type 1 diabetes, several hospitals have emerged as leaders in groundbreaking clinical trials. In Minneapolis, the University of Minnesota has been at the forefront with seven ongoing trials focused on type 1 diabetes. With an impressive track record of 48 completed studies since their first recorded trial in 1983, this institution continues to contribute significantly to medical advancements in this field. Meanwhile, over on the East Coast in Boston, the renowned Joslin Diabetes Center is also making strides. They currently have seven active clinical trials centered around type 1 diabetes and boast an extensive portfolio of 59 completed studies dating back to their initial trial in 1994.
On the West Coast, Stanford University stands out with its contributions to research on type 1 diabetes. The institution currently has five active clinical trials dedicated to exploring new treatments for this condition. Since recording their first trial related to type 1 diabetes in 1994, they have accumulated a respectable total of 57 completed studies that have helped shape our understanding of this complex disease.
Heading southwards brings us to Gainesville where researchers at the University of Florida are hard at work conducting four current clinical trials related specifically to type one diabetes while having a countable tally adding up till forty-two prior conducted investigations since starting such pioneering efforts way back until1997.Moreover,the Canadian hospital situated at Edmonton namely;University Of Alberta despite being relatively smaller scale when it comes down merely three running projects for Type I Diabetes however makes notable contribution by paving path through twenty previously held similar investigations;having started as recently as early millennium committedly devoting themselves wholeheartedly since2002 focussing primarily upon providing innovative solutions like transplantation techniques or alternative insulin delivery methods
These esteemed institutions lead not only by example but also propel hope within individuals affected by Type I Diabetes worldwide.These progressive endeavours across continents highlights how every study carried out plays a crucial role towards combating the challenges posed by this condition and signifies dedication to enhance quality of life for those living with Type I Diabetes.
Which are the best cities for type 1 diabetes clinical trials?
When it comes to type 1 diabetes clinical trials, several cities have emerged as leading hubs of research and innovation. Boston, Massachusetts takes the lead with 10 active trials investigating treatments like Afrezza (Technosphere Insulin) + insulin degludec, VX-880, and IMCY-0098 450 μg. Montreal, Quebec closely follows with 9 ongoing studies exploring interventions such as Group education sessions for parents plus usual diabetes care and Rapid-Acting Insulin. Aurora, Colorado also stands out with its focus on Semaglutide, teplizumab, and Antithymocyte globulin (ATG) in their 9 active trials. These cities offer individuals living with type 1 diabetes access to cutting-edge clinical trials that hold promise for improved management and potential breakthroughs in care.
Which are the top treatments for type 1 diabetes being explored in clinical trials?
Exciting advancements are underway in clinical trials for type 1 diabetes, with several promising treatments taking center stage. Intraportal infusion of islet cells has emerged as a frontrunner, currently being explored in three active trials and four all-time trials since its introduction in 2003. Another noteworthy contender is intervention therapy, which shows promise with two ongoing trials and one previous trial recorded since 2017. Additionally, semaglutide is making waves in the research landscape, currently under investigation in two active studies and having participated in three type 1 diabetes trials overall since its initial listing last year. These innovative approaches bring hope to individuals living with type 1 diabetes while researchers continue their tireless efforts to uncover new breakthroughs.
What are the most recent clinical trials for type 1 diabetes?
Recent clinical trials have brought new hope for individuals with type 1 diabetes. One noteworthy trial investigated the use of Ritlecitinib, a medication in Phase 2 development, which demonstrated potential benefits for managing the condition. Another promising study focused on ZT-01 7 mg, also in Phase 2 testing, showing promise as a treatment option. Additionally, an ongoing Phase 4 trial evaluated the combined use of Afrezza (Technosphere Insulin) and insulin degludec to optimize blood sugar control in type 1 diabetes patients. These advancements offer optimism for improved management and quality of life for those living with this chronic disease.
What type 1 diabetes clinical trials were recently completed?
Several groundbreaking clinical trials for type 1 diabetes have recently come to a close, bringing hope and potential advancements in the treatment of this chronic condition. Eli Lilly and Company's trial on Lyumjev concluded in February 2022, while CRISPR Therapeutics AG wrapped up their study on VCTX210A unit just a month prior in January 2022. In June 2021, Youngene Therapeutics Inc., Ltd.'s trial on YG1699 reached completion. Earlier milestones include Novo Nordisk A/S's exploration of insulin icodec in April 2021 and Mayo Clinic's investigation into Pneumovax 23- pneumococcal polysaccharide during that same period. These recent achievements reflect the dedication of researchers committed to advancing our understanding and management of type 1 diabetes.